Siemens Healthineers SHL.DE
What does Siemens Healthineers do?
Siemens Healthineers develops, manufactures and sells medical technology products and services for diagnostics and therapy. The company is divided into four segments: Imaging (magnetic resonance imaging, computed tomography, X-ray, molecular imaging, ultrasound and software for diagnostic reading), Diagnostics (laboratory and point-of-care diagnostics), Varian (radiation therapy and oncology solutions) and Advanced Therapies (image-guided minimally invasive procedures).
Customers are mainly hospitals, laboratory operators and other healthcare institutions worldwide. Revenue arises both from the sale of equipment and from recurring revenue through service, maintenance, software and consumables such as reagents. In competition, the company is among the globally leading providers in imaging and laboratory diagnostics and competes there with other large medical technology and diagnostics groups. The broad product range, a large installed equipment base and the combination of hardware, software and services form key competitive advantages.
Score profile
Rank vs. Medical Devices (50 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.
Metrics compared with the industry
On profitability and quality, Siemens Healthineers ranks in the middle in the group Medical Devices (5.0/10). On growth, the company ranks below average in the group Medical Devices (3.8/10). On valuation (higher = cheaper), the stock ranks in the middle in the group Medical Devices (5.6/10). On financial strength, Siemens Healthineers ranks below average in the group Medical Devices (3.6/10).
| Metric | Stock | Group median | Ranking |
|---|---|---|---|
| Forward P/E | 16.7x | 19.3x | better than 63 % |
| Trailing P/E | 22.3x | 26.1x | better than 67 % |
| PEG ratio | 2.2x | 1.8x | better than 37 % |
| EV/EBITDA | 13.9x | 17.3x | better than 67 % |
| Price/sales | 2.1x | 2.9x | better than 59 % |
| Price/book | 2.5x | 2.5x | better than 53 % |
| Revenue growth | 7.3% | 7.0% | better than 53 % |
| Earnings growth | -0.8% | 0.0% | better than 23 % |
| Gross margin | 38.6% | 59.5% | better than 13 % |
| Operating margin | 13.5% | 10.1% | better than 61 % |
| Net margin | 9.4% | 5.5% | better than 57 % |
| Return on equity | 11.8% | 7.9% | better than 70 % |
| Debt/equity | 74.0% | 55.4% | better than 34 % |
| Current ratio | 1.2x | 2.5x | better than 9 % |
| Free cash flow yield | 3.5% | 2.6% | better than 66 % |
| Dividend yield | 2.3% | 1.6% | – |
| Payout ratio | 50.8% | 38.0% | – |
| Beta | 0.89 | 1.05 | – |
Valuation: what is Siemens Healthineers worth?
Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Siemens Healthineers a model range of 31.97 EUR to 57.16 EUR per share.
20 analysts, average rating “Buy”, average price target 46.74 EUR (+6.3%).
The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.
What the business depends on
- The willingness of hospitals and healthcare systems to invest largely determines demand for imaging and therapy systems.
- Recurring revenue from service, software and reagents stabilizes the business and is tied to the installed equipment base.
- Technological innovation, for example in imaging, radiation therapy and AI-supported software, secures competitiveness and pricing power.
Risks
- Regulatory requirements, approval procedures and reimbursement decisions can delay product launches and put pressure on prices.
- Trade conflicts, tariffs and exchange rate fluctuations weigh on a business with a strong international orientation and global supply chains.
- Government austerity measures and cyclical budget cuts in healthcare can postpone customers' investments in large equipment.
What to look for with Siemens Healthineers
The development of order intake in relation to revenue is informative because it indicates the future capacity utilization of the project-driven equipment business.